308 related articles for article (PubMed ID: 31221661)
21. Impact of comorbidity indexes on non-relapse mortality.
Xhaard A; Porcher R; Chien JW; de Latour RP; Robin M; Ribaud P; Rocha V; Devergie A; Ferry C; Martin PJ; Socié G
Leukemia; 2008 Nov; 22(11):2062-9. PubMed ID: 18685612
[TBL] [Abstract][Full Text] [Related]
22. Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.
Middeke JM; Herbst R; Parmentier S; Bug G; Hänel M; Stuhler G; Schäfer-Eckart K; Rösler W; Klein S; Bethge W; Bitz U; Büttner B; Knoth H; Alakel N; Schaich M; Morgner A; Kramer M; Sockel K; von Bonin M; Stölzel F; Platzbecker U; Röllig C; Thiede C; Ehninger G; Bornhäuser M; Schetelig J
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1491-1497. PubMed ID: 28527985
[TBL] [Abstract][Full Text] [Related]
23. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study.
Raimondi R; Tosetto A; Oneto R; Cavazzina R; Rodeghiero F; Bacigalupo A; Fanin R; Rambaldi A; Bosi A
Blood; 2012 Aug; 120(6):1327-33. PubMed ID: 22740454
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT.
Christopeit M; Labopin M; Gorin NC; Saraceni F; Passweg J; Forcade E; Maertens J; Van Lint MT; Bosi A; Niederwieser D; Ehninger G; Polge E; Mohty M; Nagler A
Am J Hematol; 2018 Dec; 93(12):1532-1542. PubMed ID: 30218444
[TBL] [Abstract][Full Text] [Related]
25. Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study.
Shouval R; Labopin M; Unger R; Giebel S; Ciceri F; Schmid C; Esteve J; Baron F; Gorin NC; Savani B; Shimoni A; Mohty M; Nagler A
PLoS One; 2016; 11(3):e0150637. PubMed ID: 26942424
[TBL] [Abstract][Full Text] [Related]
26. The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation--investigation of potential limitations of the index.
Birninger N; Bornhäuser M; Schaich M; Ehninger G; Schetelig J
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1822-32. PubMed ID: 21708108
[TBL] [Abstract][Full Text] [Related]
27. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Lee HC; Saliba RM; Rondon G; Chen J; Charafeddine Y; Medeiros LJ; Alatrash G; Andersson BS; Popat U; Kebriaei P; Ciurea S; Oran B; Shpall E; Champlin R
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1948-54. PubMed ID: 26183077
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
Wang CY; Ren HY; Qiu ZX; Wang Y; Cen XN; Wang LH; Wang MJ; Xu WL; Wang WS; Li Y; Dong YJ; Ou JP; Liang ZY; Liu W; Wang Q
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
[TBL] [Abstract][Full Text] [Related]
29. Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post-transplant cyclophosphamide.
Jullien M; Orvain C; Berceanu A; Couturier MA; Guillaume T; Peterlin P; Garnier A; Le Bourgeois A; Klemencie M; Schmidt A; Hunault M; Daguindau E; Roussel X; Delepine P; Guillerm G; Giltat A; François S; Thepot S; Le Gouill S; Béné MC; Chevallier P
Cancer Med; 2021 Oct; 10(20):7194-7202. PubMed ID: 34547182
[TBL] [Abstract][Full Text] [Related]
30. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML.
Lim ZY; Ingram W; Brand R; Ho A; Kenyon M; Devereux S; Marsh J; Mufti GJ; Pagliuca A
Bone Marrow Transplant; 2010 Apr; 45(4):633-9. PubMed ID: 19767782
[TBL] [Abstract][Full Text] [Related]
31. Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation.
Lucchini G; Labopin M; Beohou E; Dalissier A; Dalle JH; Cornish J; Zecca M; Samarasinghe S; Gibson B; Locatelli F; Bertrand Y; Abdel-Rahman F; Socie G; Sundin M; Lankester A; Sedlacek P; Hamladji RM; Heilmann C; Afanasyev B; Hough R; Peters C; Bader P; Veys P
Biol Blood Marrow Transplant; 2017 Mar; 23(3):467-474. PubMed ID: 27916512
[TBL] [Abstract][Full Text] [Related]
32. Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation.
Vaughn JE; Storer BE; Armand P; Raimondi R; Gibson C; Rambaldi A; Ciceri F; Oneto R; Bruno B; Martin PJ; Sandmaier BM; Storb R; Sorror ML
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1418-24. PubMed ID: 25862589
[TBL] [Abstract][Full Text] [Related]
33. Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation.
Gjærde LK; Ostrowski SR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
Transplant Cell Ther; 2023 Feb; 29(2):97.e1-97.e6. PubMed ID: 36375798
[TBL] [Abstract][Full Text] [Related]
34. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
35. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
Sakellari I; Mallouri D; Gavriilaki E; Batsis I; Kaliou M; Constantinou V; Papalexandri A; Lalayanni C; Vadikolia C; Athanasiadou A; Yannaki E; Sotiropoulos D; Smias C; Anagnostopoulos A
Biol Blood Marrow Transplant; 2017 Mar; 23(3):445-451. PubMed ID: 27914967
[TBL] [Abstract][Full Text] [Related]
36. Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study.
Shouval R; Labopin M; Bondi O; Mishan-Shamay H; Shimoni A; Ciceri F; Esteve J; Giebel S; Gorin NC; Schmid C; Polge E; Aljurf M; Kroger N; Craddock C; Bacigalupo A; Cornelissen JJ; Baron F; Unger R; Nagler A; Mohty M
J Clin Oncol; 2015 Oct; 33(28):3144-51. PubMed ID: 26240227
[TBL] [Abstract][Full Text] [Related]
37. Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy.
Nakaya A; Mori T; Tanaka M; Tomita N; Nakaseko C; Yano S; Fujisawa S; Sakamaki H; Aotsuka N; Yokota A; Kanda Y; Sakura T; Nanya Y; Saitoh T; Kanamori H; Takahashi S; Okamoto S
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1553-9. PubMed ID: 25034961
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources.
Elsawy M; Storer BE; Milano F; Sandmaier BM; Delaney C; Salit RB; Rashad AH; Woolfrey AE; Appelbaum FR; Storb R; Sorror ML
Biol Blood Marrow Transplant; 2019 May; 25(5):1045-1052. PubMed ID: 30500442
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.
Ishida H; Kato M; Kudo K; Taga T; Tomizawa D; Miyamura T; Goto H; Inagaki J; Koh K; Terui K; Ogawa A; Kawano Y; Inoue M; Sawada A; Kato K; Atsuta Y; Yamashita T; Adachi S
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2141-2147. PubMed ID: 26271192
[TBL] [Abstract][Full Text] [Related]
40. Validation of the acute leukemia-EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort.
Shouval R; Bonifazi F; Fein J; Boschini C; Oldani E; Labopin M; Raimondi R; Sacchi N; Dabash O; Unger R; Mohty M; Rambaldi A; Nagler A
Am J Hematol; 2017 May; 92(5):429-434. PubMed ID: 28181279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
